Overview

Photodynamic Therapy With LUZ11 in Advanced Head and Neck Cancer

Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This study will investigate the tolerability, recommended dose and pharmacokinetics of LUZ11 following photodynamic therapy (PDT) of patients with advanced head and neck cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Luzitin SA